Viewing Study NCT05030506


Ignite Creation Date: 2025-12-26 @ 1:16 PM
Ignite Modification Date: 2026-01-01 @ 2:11 AM
Study NCT ID: NCT05030506
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-18
First Post: 2021-08-30
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module